文献速递血栓与止血

延长半衰期rFVIIIFc在重型A型血友病初治患者中的首次研究:PUPs A-LONG最终结果

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results.
PubMed 文献 · Blood · 2022-01-01

PUPs A-LONG是一项开放标签3期研究,纳入103例接受至少1剂rFVIIIFc的男性重型A型血友病初治患儿(<6岁),主要终点为抑制物发生。暴露日≥10天(或发生抑制物)者抑制物发生率为31.1%(95%CI 21.8%–41.7%),高滴度抑制物发生率为15.6%(95%CI 8.8%–24.7%);rFVIIIFc耐受良好,对预防和治疗出血有效。

要点

  • 暴露日≥10天(或发生抑制物)者抑制物发生率31.1%(95%CI 21.8%–41.7%),高滴度抑制物发生率15.6%(95%CI 8.8%–24.7%)。
  • 高滴度抑制物发生的中位(范围)时间为9(4–14)个暴露日。
  • 可变预防方案下总体中位(四分位距)年化出血率为1.49(0.00–4.40)。

核心结论

  • 在重型A型血友病初治患儿中,rFVIIIFc总体抑制物发生处于预期范围内,高滴度抑制物发生处于文献报道范围的低端。
  • rFVIIIFc耐受良好,对预防和治疗出血有效。

研究设计与样本

  • 开放标签3期研究,纳入103例接受至少1剂rFVIIIFc的男性重型A型血友病初治患儿(<6岁)。
  • 主要终点为抑制物发生,次要终点包括年化出血率;试验注册号NCT02234323。

主要发现

  • 103例受试者中80例(78%)在研究开始时年龄<1岁,20例(19%)有抑制物家族史,82例(80%)携带高风险F8突变。
  • 20例以预防治疗开始,81例以按需治疗开始(其中69例后来转为预防治疗);87例(81%)完成研究。
  • 暴露日≥10天(或发生抑制物)者抑制物发生率为31.1%(95%CI 21.8%–41.7%),高滴度抑制物发生率为15.6%(95%CI 8.8%–24.7%)。
  • 高滴度抑制物发生的中位(范围)时间为9(4–14)个暴露日。
  • 28例(27%)受试者发生32起rFVIIIFc治疗相关不良事件,多数为抑制物发生;有1例非治疗相关死亡,死因为颅内出血(发生于首剂rFVIIIFc之前)。

关键数值与推荐

  • 暴露日≥10天(或发生抑制物)者抑制物发生率31.1%(95%CI 21.8%–41.7%)。
  • 暴露日≥10天(或发生抑制物)者高滴度抑制物发生率15.6%(95%CI 8.8%–24.7%)。
  • 可变预防方案下总体中位(四分位距)年化出血率为1.49(0.00–4.40)。

临床怎么用

  • 作者认为,rFVIIIFc在该初治患儿研究中耐受良好,对预防和治疗出血有效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PUPs A-LONG evaluated the safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously untreated patients (PUPs) with hemophilia A. This open-label, phase 3 study enrolled male PUPs (<6 years) with severe hemophilia A to receive rFVIIIFc. The primary endpoint was the occurrence of inhibitor development. Secondary endpoints included annualized bleed rate (ABR). Of 103 subjects receiving ≥1 dose of rFVIIIFc, 80 (78%) were aged <1 year at the study start, 20 (19%) had a family history of inhibitors, and 82 (80%) had high-risk F8 mutations. Twenty subjects began on prophylaxis, while 81 began an on-demand regimen (69 later switched to prophylaxis). Eighty-seven (81%) subjects completed the study. Inhibitor incidence was 31.1% (95% confidence interval [CI], 21.8% to 41.7%) in subjects with ≥10 exposure days (or inhibitor); high-titer inhibitor incidence was 15.6% (95% CI, 8.8% to 24.7%). The median (range) time to high-titer inhibitor development was 9 (4-14) exposure days. Twenty-eight (27%) subjects experienced 32 rFVIIIFc treatment-related adverse events; most were inhibitor development. There was 1 nontreatment-related death due to intracranial hemorrhage (onset before the first rFVIIIFc dose). The overall median (interquartile range [IQR]) ABR was 1.49 (0.00-4.40) for subjects on variable prophylaxis dosing regimens. In this study of rFVIIIFc in pediatric PUPs with severe hemophilia A, overall inhibitor development was within the expected range, although high-titer inhibitor development was on the low end of the range reported in the literature. rFVIIIFc was well-tolerated and effective for prophylaxis and treatment of bleeds. This trial is registered at www.clinicaltrials.gov (NCT02234323).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022. PMID: 35421219. doi:10.1182/blood.2021013563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。